MedWatch

Snipr Biome to send first candidate to clinic

The FDA has given Danish CRISPR company Snipr Biome the thumbs-up to begin clinical testing of its drug candidate that targets E. coli infections. A phase I trial is scheduled to begin in the first half of 2022.

Christian Grøndahl, co-founder and CEO of Snipr, can look forward to an exciting year ahead, as the company can begin clinically testing its first development candidate | Photo: EY / PR

CRISPR company Snipr Biome has an exciting year ahead, as the US Food and Drug Administration (FDA) has approved the company's application to initiate a phase I clinical trial with the company's first development candidate, SNIPR001, which is designed to target E. coli in the gut, a press release announces.

"The Snipr Biome team is excited about this important milestone, and we are looking forward to initiating the clinical trial in the US later this year, testing our unique CRISPR technology. SNIPR001 is our most progressed asset, and we are very proud of the team effort that brought us here," Co-Founder and CEO at Snipr Christian Grøndahl says in the statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs